Alpha globin gene copy number and incident ischemic stroke risk among Black Americans

A. Parker Ruhl, Neal Jeffries, Yu Yang, Steven Brooks, Rakhi P. Naik, Lydia H. Pecker, Bryan T. Mott, Cheryl A. Winkler, Nicole D. Armstrong, Neil A. Zakai, Orlando M. Gutierrez, Suzanne Judd, Virginia Howard, George Howard, Marguerite R. Irvin, Mary Cushman, Hans C. Ackerman

Correspondence: A. Parker Ruhl, MD, 10 Center Dr., B3-4207, Bethesda, MD, 20892. parker.ruhl@nih.gov

ABSTRACT

Introduction: People with African ancestry have greater stroke risk and greater heritability of stroke risk than people of other ancestries. Given the importance of NO in stroke, we examined the association between alpha globin gene (*HBA)* copy number and incident ischemic stroke in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.

Methods: Among 9,999 Black REGARDS participants[9] with *HBA* and *HBB* genotyping available, 8,947 participants had no self-reported history of stroke at baseline and complete follow-up data. Incident ischemic stroke was defined as non-hemorrhagic stroke with a focal neurological deficit lasting ≥ 24 hours confirmed by the medical record or a focal or non-focal neurological deficit with positive imaging confirmed with medical records. Genomic DNA was analyzed using droplet digital PCR to determine *HBA* copy number. Multivariable Cox proportional hazards regression was used to estimate the hazard ratio (HR) of *HBA* copy number on time to first ischemic stroke.

Results: Four-hundred seventy-nine (5.3%) participants had an ischemic stroke over a median (IQR) of 11.0 (5.7, 14.0) years' follow-up. *HBA* gene copy number ranged from 2 to 6: 368 (4%) -α/-α, 2,480 (28%) -α/αα, 6,014 (67%) αα/αα, 83 (1%) ααα/αα and 2 (<1%) ααα/ααα. The HR of ischemic stroke with *HBA* copy number, adjusted for age, sex, hypertension, atrial fibrillation, LVH, diabetes, and smoking, was 1.04; 95%CI 0.89, 1.21; p = 0.66.

Conclusions: Although a reduction in *HBA* copy number is expected to increase endothelial nitric oxide signaling in the human vascular endothelium, *HBA* copy number was not associated with incident ischemic stroke in this large longitudinal cohort of Black Americans. This finding is consistent with a prior study demonstrating no association between *HBA* copy number and

hypertension but differs from a study demonstrating an association with chronic and end-stage kidney disease in which *HBA* gene deletions are protective. Together, these population studies suggest that the physiological roles of alpha globin may differ between the renal and cerebral vascular beds.

INTRODUCTION

People with African ancestry have greater stroke risk and greater heritability of stroke risk than people of other ancestries.[1,2] While some risk is explained by genetic variants shared between European and African populations, less is known about African-specific variants.[3] Alpha globin (*HBA*), which regulates endothelial nitric oxide (NO) signaling in resistance arteries, varies in gene copy number among people of African and Asian descent.[4,5] Genetic deletion of *HBA* is associated with protection from kidney disease, possibly through increased vascular NO signaling.[6] Given the importance of NO in stroke,[7,8] we examined the association between *HBA* copy number and incident ischemic stroke in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.[9]

METHODS

Among 9,999 Black REGARDS participants[9] with *HBA* and *HBB* genotyping available, 8,947 participants had no self-reported history of stroke at baseline and complete follow-up data (Figure S1) (additional methods in Supplemental Material). Incident ischemic stroke was defined as non-hemorrhagic stroke with a focal neurological deficit lasting ≥ 24 hours confirmed by the medical record or a focal or non-focal neurological deficit with positive imaging confirmed with medical records. Genomic DNA was analyzed using droplet digital PCR [6] to determine *HBA* copy number. Multivariable Cox proportional hazards regression was used to estimate the hazard ratio (HR) of *HBA* copy number on time to first ischemic stroke (see Supplemental Material). Pre-specified tests of interaction with age, sex, and sickle cell trait were and *HBA* copy number were performed on fully adjusted models. Pre-specified sensitivity analyses individually adding adjustment factors were performed: the first ten principal components of ancestry (PCA), *HBA* regulatory single nucleotide polymorphisms (SNP) rs11248850 and rs7203560, hemoglobin, chronic kidney disease (CKD), hemoglobin and CKD together, regular aspirin use, and regular statin use.

RESULTS

Four-hundred seventy-nine (5.3%) participants had an ischemic stroke over a median (IQR) of 11.0 (5.7, 14.0) years' follow-up (Figure S1). *HBA* gene copy number ranged from 2 to 6: 368 (4%) -α/-α, 2,480 (28%) -α/αα, 6,014 (67%) αα/αα, 83 (1%) ααα/αα and 2 (<1%) ααα/ααα (Table S1). The HR of ischemic stroke with *HBA* copy number, adjusted for age, sex, hypertension, atrial fibrillation, LVH, diabetes, and smoking, was 1.04; 95%CI 0.89, 1.21; p = 0.66; (Table S2). There were no interactions between *HBA* copy number and age, sex, or sickle cell trait (Table S3). In pre-specified sensitivity analyses, the addition of hemoglobin, chronic kidney disease, aspirin use, statin use, or the first ten principal components of ancestry did not materially change the observed associations (Table S4.)

CONCLUSIONS

Although a reduction in *HBA* copy number is expected to increase endothelial nitric oxide signaling in the human vascular endothelium, *HBA* copy number was not associated with incident ischemic stroke in this large longitudinal cohort of Black Americans. This finding is consistent with a prior study demonstrating no association between *HBA* copy number and hypertension but differs from a study demonstrating an association with chronic and end-stage kidney disease in which *HBA* gene deletions are protective.[6,10] Together, these population studies suggest that the physiological roles of alpha globin may differ between the renal and cerebral vascular beds.

REFERENCES

1. Prapiadou S, Demel SL, Hyacinth HI. Genetic and Genomic Epidemiology of Stroke in People of African Ancestry. *Genes*. 2021;12:1825.

2. Howard G, Cushman M, Kissela BM, Kleindorfer DO, McClure LA, Safford MM, Rhodes JD, Soliman EZ, Moy CS, Judd SE, Howard VJ. Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass. *Stroke*. 2011;42.

3. Traylor M, Rutten-Jacobs L, Curtis C, Patel H, Breen G, Newhouse S, Lewis CM, Markus HS. Genetics of stroke in a UK African ancestry case-control study: South London Ethnicity and Stroke Study. *Neurol Genet*. 2017;3:e142.

4. Straub AC, Lohman AW, Billaud M, Johnstone SR, Dwyer ST, Lee MY, Bortz PS, Best AK, Columbus L, Gaston B, Isakson BE. Endothelial cell expression of haemoglobin α regulates nitric oxide signalling. *Nature*. 2012;491:473–477.

5. Dozy AM, Kan YW, Embury SH, Mentzer WC, Wang WC, Lubin B, Davis JR, Koenig HM. alpha-Globin gene organisation in blacks precludes the severe form of alpha-thalassaemia. *Nature*. 1979;280:605–607.

6. Ruhl AP, Jeffries N, Yang Y, Naik RP, Patki A, Pecker LH, Mott BT, Zakai NA, Winkler CA, Kopp JB, Lange LA, Irvin MR, Gutierrez OM, Cushman M, Ackerman HC. Alpha Globin Gene Copy Number Is Associated with Prevalent Chronic Kidney Disease and Incident End-Stage Kidney Disease among Black Americans. *J Am Soc Nephrol*. 2022;33:213–224.

7. Garry PS, Ezra M, Rowland MJ, Westbrook J, Pattinson KTS. The role of the nitric oxide pathway in brain injury and its treatment — From bench to bedside. *Exp Neurol*. 2015;263:235–243.

8. Woodhouse L, Scutt P, Krishnan K, Berge E, Gommans J, Ntaios G, Wardlaw J, Sprigg N, Bath PM. Effect of Hyperacute Administration (Within 6 Hours) of Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, on Outcome After Stroke. *Stroke*. 2015;46:3194–3201.

9. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G. The reasons for geographic and racial differences in stroke study: objectives and design. *Neuroepidemiology*. 2005;25.

10. Ruhl AP, Jeffries N, Yang Y, Gutierrez OM, Muntner P, Naik RP, Pecker LH, Mott BT, Zakai NA, Safford MM, Lange LA, Winkler CA, Irvin MR, Cushman M, Ackerman HC. Alpha globin gene copy number and hypertension risk among Black Americans. *PLOS ONE*. 2022;17:e0271031.

AFFILIATIONS
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (A.P.R., S.B., H.C.A.); National Heart, Lung, and Blood Institute, Bethesda, Maryland (A.P.R., N.J., Y.Y.); Johns Hopkins University School of Medicine, Baltimore, Maryland (R.P.N., L.H.P.); University of Alabama at Birmingham, Birmingham, Alabama (N.D.A., O.M.G, S.J., V.H., G.H., M.R.I); Wake Forest University School of Medicine, Winston-Salem, North Carolina (B.T.M); National Cancer Institute, Frederick, Maryland (C.W.); Larner College of Medicine, Burlington, Vermont (N.A.Z., M.C.)

DATA AVAILABILITY

Data are available from the University of Alabama at Birmingham (regardsadmin@uab.edu). The genetic data is available in dbGaP with study accession number phs002719.v1.p1.

FUNDING
NIH U01 NS041588 (M.C.); AI001150 (H.C.A), HL006196 (H.C.A.); HHSN26120080001E (C.A.W); K08HL12510 (R.P.N.) and K08HL096841 (N.A.Z.).

DISCLOSURES
Dr. Gutierrez receives funding from GlaxoSmithKline; consulting fees from Reata, AstraZeneca, and Ardelyx; funding and consulting fees from Akebia Therapeutics, Amgen. He serves on a data monitoring committee for QED Therapeutics.